Acute Coronary Syndrome Clinical Trial
Official title:
Effect of Continuous Clopidogrel Dosing Targeted After Platelet Function Testing in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention With High On-treatment Platelet Reactivity
The purpose of this study is to determine whether continuous clopidogrel dose adjustment targeted after platelet function testing improves outcomes during 12 months of follow-up in acute coronary syndrome patients treated with coronary artery stenting and with determined high platelet reactivity on clopidogrel.
Dual antiplatelet therapy (DAPT) with aspirin and P2Y12 receptor antagonists during 12
months presents cornerstone treatment in acute coronary syndrome (ACS) patients undergoing
percutaneous coronary intervention (PCI). Clopidogrel is the most widely used P2Y12
inhibitor despite it's limitations that include highly variable P2Y12-receptor inhibition
which causes wide interindividual platelet reactivity variability. Since high on-treatment
platelet reactivity (HTPR) on clopidogrel is strongly associated with adverse events,
antiplatelet therapy tailoring has been vastly investigated to determine whether
individualized approach could improve outcomes. In the time of progressive personalized
approach to therapy, effective strategies are needed to minimize the risk of ischemic
adverse events without increasing the risk for bleeding.
Aim of this study is to investigate whether continuous clopidogrel dose adjustment according
to platelet function testing (PFT) using Multiplate® function analyzer (Roche Diagnostics,
Mannheim, Germany) could decrease the rate of adverse events in ACS patients treated with
PCI and with HTPR during early and late period of DAPT treatment.
Cut off values for HTPR and enhanced platelet response were set according to the consensus
statement at >46 U and <19 U, respectively. PFT and therapy tailoring was performed at day
1, 2, 3, 7, 30 and month 2, 3, 6, 9 and 12.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06013813 -
Conventional vs. Distal Radial Access Outcomes in STEMI Patients Treated by PCI
|
N/A | |
| Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
| Recruiting |
NCT05412927 -
AngelMed Guardian® System PMA Post Approval Study
|
||
| Completed |
NCT02750579 -
Early or Delayed Revascularization for Intermediate and High-risk Non ST-elevation Acute Coronary Syndromes?
|
N/A | |
| Completed |
NCT04102410 -
Assessing Force-velocity Profile: an Innovative Approach to Optimize Cardiac Rehabilitation in Coronary Patients
|
N/A | |
| Enrolling by invitation |
NCT03342131 -
Serum Concentration of Wnt2 and Wnt4 in Patients With Acute Coronary Syndrome
|
N/A | |
| Recruiting |
NCT01218776 -
International Survey of Acute Coronary Syndromes in Transitional Countries
|
||
| Enrolling by invitation |
NCT04676100 -
International CR Registry
|
||
| Completed |
NCT03590535 -
5th Generation cTnT in ED ACS
|
||
| Recruiting |
NCT05437900 -
INSIGHTFUL-FFR Clinical Trial
|
Phase 4 | |
| Completed |
NCT05551429 -
Factors Related to Participation in Cardiac Rehabilitation in Patients With Acute Coronary Syndrome
|
||
| Terminated |
NCT04316481 -
IDE-ALERTS Continued Access Study
|
N/A | |
| Active, not recruiting |
NCT04475380 -
Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
|
||
| Not yet recruiting |
NCT04852146 -
Electronic Feedback for Data Restitution and Valorization to the Emergency Teams in Aquitaine.
|
||
| Active, not recruiting |
NCT02892903 -
In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes?
|
N/A | |
| Completed |
NCT04077229 -
Piloting Text Messages to Promote Positive Affect and Physical Activity
|
N/A | |
| Not yet recruiting |
NCT02871622 -
BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM
|
N/A | |
| Completed |
NCT02944123 -
Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR)
|
Phase 3 | |
| Active, not recruiting |
NCT02922140 -
The Impact of Pharmaceutical Care Practice on Patients in Cardiac Rehabilitation Unit
|
N/A | |
| Terminated |
NCT02620202 -
Aiming Towards Evidence Based Interpretation of Cardiac Biomarkers in Patients Presenting With Chest Pain
|